Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age
Vaccination offers the best way to prevent invasive meningococcal disease (IMD). As demonstrated in countries with national immunization programs (NIPs) against IMD, meningococcal conjugate vaccines have contributed to significant declines in incidence. Since some meningococcal vaccines are associat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2099142 |
| _version_ | 1797673159396163584 |
|---|---|
| author | Gary S. Marshall Stephen I. Pelton Corwin A. Robertson Philipp Oster |
| author_facet | Gary S. Marshall Stephen I. Pelton Corwin A. Robertson Philipp Oster |
| author_sort | Gary S. Marshall |
| collection | DOAJ |
| description | Vaccination offers the best way to prevent invasive meningococcal disease (IMD). As demonstrated in countries with national immunization programs (NIPs) against IMD, meningococcal conjugate vaccines have contributed to significant declines in incidence. Since some meningococcal vaccines are associated with modest immunogenicity in infants, possible immunological interference upon concomitant administration with some pediatric vaccines, and administration errors resulting from improper reconstitution, opportunities for improvement exist. A quadrivalent conjugate vaccine, MenQuadfi® (Meningococcal [Serogroups A, C, Y, and W] Conjugate Vaccine; Sanofi, Swiftwater, Pennsylvania), was approved in 2020 for the prevention of IMD caused by meningococcal serogroups A, C, W, and Y in individuals ≥2 years of age in the United States. Five pivotal studies and one ancillary study supported approval in the United States; clinical trials in infants are ongoing. Data on the immunogenicity and safety of this vaccine are presented, and its potential value in clinical practice is discussed. |
| first_indexed | 2024-03-11T21:40:41Z |
| format | Article |
| id | doaj.art-6a2523a28368416cb2c7cd3c9c925ee4 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:40:41Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-6a2523a28368416cb2c7cd3c9c925ee42023-09-26T13:19:08ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118610.1080/21645515.2022.20991422099142Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of ageGary S. Marshall0Stephen I. Pelton1Corwin A. Robertson2Philipp Oster3Norton Children’s and University of Louisville School of MedicineBoston University School of MedicineSanofi, Discovery DriveSanofiVaccination offers the best way to prevent invasive meningococcal disease (IMD). As demonstrated in countries with national immunization programs (NIPs) against IMD, meningococcal conjugate vaccines have contributed to significant declines in incidence. Since some meningococcal vaccines are associated with modest immunogenicity in infants, possible immunological interference upon concomitant administration with some pediatric vaccines, and administration errors resulting from improper reconstitution, opportunities for improvement exist. A quadrivalent conjugate vaccine, MenQuadfi® (Meningococcal [Serogroups A, C, Y, and W] Conjugate Vaccine; Sanofi, Swiftwater, Pennsylvania), was approved in 2020 for the prevention of IMD caused by meningococcal serogroups A, C, W, and Y in individuals ≥2 years of age in the United States. Five pivotal studies and one ancillary study supported approval in the United States; clinical trials in infants are ongoing. Data on the immunogenicity and safety of this vaccine are presented, and its potential value in clinical practice is discussed.http://dx.doi.org/10.1080/21645515.2022.2099142immunogenicityinvasive meningococcal diseaseimdmenacwy-crmmenacwy-dmenacwy-ttmenacyw-ttmenquadfimeningococcal conjugate vaccinesafetyvaccine recommendations |
| spellingShingle | Gary S. Marshall Stephen I. Pelton Corwin A. Robertson Philipp Oster Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age Human Vaccines & Immunotherapeutics immunogenicity invasive meningococcal disease imd menacwy-crm menacwy-d menacwy-tt menacyw-tt menquadfi meningococcal conjugate vaccine safety vaccine recommendations |
| title | Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age |
| title_full | Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age |
| title_fullStr | Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age |
| title_full_unstemmed | Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age |
| title_short | Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age |
| title_sort | immunogenicity and safety of menacwy tt a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the united states for individuals ≥2 years of age |
| topic | immunogenicity invasive meningococcal disease imd menacwy-crm menacwy-d menacwy-tt menacyw-tt menquadfi meningococcal conjugate vaccine safety vaccine recommendations |
| url | http://dx.doi.org/10.1080/21645515.2022.2099142 |
| work_keys_str_mv | AT garysmarshall immunogenicityandsafetyofmenacwyttaquadrivalentmeningococcaltetanustoxoidconjugatevaccinerecentlylicensedintheunitedstatesforindividuals2yearsofage AT stephenipelton immunogenicityandsafetyofmenacwyttaquadrivalentmeningococcaltetanustoxoidconjugatevaccinerecentlylicensedintheunitedstatesforindividuals2yearsofage AT corwinarobertson immunogenicityandsafetyofmenacwyttaquadrivalentmeningococcaltetanustoxoidconjugatevaccinerecentlylicensedintheunitedstatesforindividuals2yearsofage AT philipposter immunogenicityandsafetyofmenacwyttaquadrivalentmeningococcaltetanustoxoidconjugatevaccinerecentlylicensedintheunitedstatesforindividuals2yearsofage |